Trial Profile
An open-label, 3-parallel panel, 3-period, Pharmacokinetic Interactions and tolerability study between MK-5172 and Ritonavir-Boosted HIV Protease Inhibitors (Atazanavir, Lopinavir, Darunavir) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary) ; Atazanavir; Darunavir; Lopinavir
- Indications Hepatitis C; HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 11 Dec 2015 New trial record